Kymera Therapeutic/$KYMR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Ticker
$KYMR
Sector
Primary listing
Employees
218
Headquarters
Website
KYMR Metrics
BasicAdvanced
$4.3B
-
-$3.48
2.18
-
Price and volume
Market cap
$4.3B
Beta
2.18
52-week high
$63.96
52-week low
$19.45
Average daily volume
712K
Financial strength
Current ratio
8.32
Quick ratio
8.059
Long term debt to equity
7.416
Total debt to equity
8.823
Interest coverage (TTM)
-996.36%
Profitability
EBITDA (TTM)
-305.056
Gross margin (TTM)
-550.56%
Net profit margin (TTM)
-616.03%
Operating margin (TTM)
-697.51%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-19.92%
Return on equity (TTM)
-33.26%
Valuation
Price to revenue (TTM)
105.839
Price to book
4.34
Price to tangible book (TTM)
4.34
Price to free cash flow (TTM)
-18.71
Free cash flow yield (TTM)
-5.34%
Free cash flow per share (TTM)
-3.192
Growth
Revenue change (TTM)
-49.51%
Earnings per share change (TTM)
43.55%
3-year revenue growth (CAGR)
-7.64%
3-year earnings per share growth (CAGR)
8.62%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Bulls say / Bears say
Phase 1 healthy volunteer results for KT-621 demonstrated over 90% average STAT6 degradation in blood and skin, along with median TARC biomarker reductions of up to 37%. The safety profile matched placebo, supporting KT-621’s promise as an oral alternative to injectable biologics and prompting a 41% jump in shares (Barron’s).
Gilead Sciences has signed an exclusive option and license deal with Kymera worth up to $750 million, including $85 million up front, validating Kymera’s molecular glue platform for oncology and supplying significant non-dilutive funding (Reuters).
After a $288 million equity raise and the Gilead upfront payment in Q2, Kymera reported about $1 billion in cash, cash equivalents, and investments as of July 31, 2025, extending its funding runway into the second half of 2028 to support multiple important clinical milestones (SEC Filing).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $4.3B as of November 04, 2025.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of November 04, 2025.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.